department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zolinza · pharmadog

pharmadog
drugs
Zolinza

drug

patient view →

vorinostat

Marketedupdated 2mo ago

by $MRK Merck & Co., Inc.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Zolinza

generic

vorinostat

indication

Cutaneous T-Cell Lymphoma

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 11, 2027

247 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Mar 18, 2028method-of-use (U-892)US 84503721.7y
Mar 11, 2027compositionUS 7456219247d
May 16, 2026formulationUS 8093295

Trials studying vorinostat

phase2TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIrecruitingn=90
phase2Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimenscompletedn=25
phase1Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Canceractive not recruitingn=28
phase2Pediatric Precision Laboratory Advanced Neuroblastoma Therapyrecruitingn=500
phase2Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)completedn=56
phase2Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancerrecruitingn=15
phase2Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)active not recruitingn=120
phase3Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphomaactive not recruitingn=790

more trials →